Medical/Pharmaceuticals
Live from ASCO 2023 | Ascentage Pharma Releases Updated Data Showing APG-2449's Potential as a New Treatment for Drug-Resistant NSCLC
SUZHOU, China and ROCKVILLE, Md., June 6, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that for the second consecutive year, it has release...
2023-06-06 12:20
3227
Live from ASCO 2023 | Ascentage Pharma Releases the First Dataset of Lisaftoclax in WM, Revealing Encouraging Therapeutic Potential
SUZHOU, China and ROCKVILLE, Md,, June 5, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that it has released preliminary results from a Phas...
2023-06-06 10:45
2209
Cali Biosciences Initiates Second Phase III Study of CPL-01 (Long-Acting Ropivacaine) to Decrease Post-Operative Pain and Reduce or Eliminate Opioid Use and Presents Consistent and Predictable PK Results Across Multiple Surgeries
* Subjects in Bunionectomy Study Dosed * Data Presented at American Society for Pharmacology and Experimental Therapeutics Shows Similar Ropivacaine Pharmacokinetic Curves From CPL-01 Across Multiple Surgeries; Minimal Variability as Compared to Liposomal Bupivacaine SAN DIEGO, June 5, 2023 ...
2023-06-06 00:00
2707
Russellville Hospital and United Imaging Announce First Installation in the U.S. of the 4 cm uCT(R) ATLAS Computed Tomography Scanner
Russellville Hospital Moved Quickly To Bring High-End Technology to Patients HOUSTON, June 5, 2023 /PRNewswire/ -- United Imaging, a global leader in manufacturing advanced medical imaging and radiotherapy equipment, confirmed that Russellville Hospital is the first customer to complete installat...
2023-06-05 22:00
2160
Fresh2 Group Ltd. Announces US$4.4 Million Private Placement
NEW YORK, June 5, 2023 /PRNewswire/ -- Fresh2 Group Ltd., formerly AnPac Bio-Medical Science Co., Ltd. (NASDAQ: FRES), a company with operations in the United States and China focused on early cancer screening and detection and plans to enter into the operation of a business-to-business e-commer...
2023-06-05 21:00
3050
Live from ASCO 2023 | For the Third Consecutive Year, Ascentage Pharma Releases Promising Results of Alrizomadlin plus Pembrolizumab in Patients with Cutaneous Melanoma that Failed Immuno-Oncologic (IO) Therapies
SUZHOU, China, and ROCKVILLE, Md., June 5, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that it has released updated results from a Phase I...
2023-06-05 17:34
2336
Lunit and Capio S:t Göran Hospital Collaborate to Address Radiologist Shortage with AI-Powered Mammography Analysis
- Lunit and Sweden's largest private hospital pioneering a new approach to combine radiologists' expertise with AI SEOUL, South Korea, June 5, 2023 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading global provider of AI-powered cancer diagnostic solutions, today announced the signing of a supply ...
2023-06-05 15:00
2072
Gencurix Announces Clinical Research Results At ASCO 2023 Demonstrating Outstanding Performance of GenesWell BCT, the Company's Breast Cancer Prognostic Test, Compared to Global Best-Selling Test, OncotypeDX
SEOUL, South Korea, June 4, 2023 /PRNewswire/ -- Gencurix
2023-06-05 14:37
2768
American Society of Clinical Oncology confers highest honor upon Prof Hagop Kantarjian
SUZHOU, China and ROCKVILLE, Md., June 5, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that its Clinical Advisory Board member ProfHago...
2023-06-05 12:30
2023
Live from ASCO 2023 | Updated Data of Olverembatinib in SDH-Deficient GIST including a CBR of 93.8% Signals a Potential Clinical Breakthrough
SUZHOU, China and ROCKVILLE, Md., June 4, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that it has released updated clinical results of olv...
2023-06-05 11:51
2183
Harbour BioMed Announces First Patient Dosed in Phase I Study of First-in-Class Anti-B7H7 (HHLA2) Antibody HBM1020
* HBM1020 is a first-in-class therapeutic monoclonal antibody against B7H7/HHLA2 entering clinical development globally. * HBM1020 was generated from Harbour Mice® H2L2 transgenic mice platform. * HBM1020 has great potential to address huge unmet medical needs in patients with advanced malig...
2023-06-05 09:01
2100
LOTTE BIOLOGICS to Kick off their CDMO Business Campaign at 'BIO International Convention 2023'
* Exclusive booth and private meeting rooms to be utilized for robust business initiatives SEOUL, South Korea, June 4, 2023 /PRNewswire/ -- LOTTE BIOLOGICS, under the leadership of CEORichard Lee, enthusiastically disclosed its participation in the upcoming 'BIO International Convention 2023' t...
2023-06-05 08:27
2227
VVN539 met primary study endpoints in US phase IIa clinical study for the treatment of glaucoma
SHANGHAI, June 4, 2023 /PRNewswire/ -- This was a Phase 2, double-masked, randomized, vehicle-controlled, dose-response study to assess the safety and ocular hypotensive efficacy of VVN539 in subjects with primary open angle glaucoma (POAG) or ocular hypertension (OHT). The primary objective was ...
2023-06-05 08:00
2119
Gracell Biotechnologies Presents Updated Data of Deep and Durable Responses for FasTCAR-T GC012F in Relapsed/Refractory Multiple Myeloma at 2023 ASCO Annual Meeting
Data on BCMA/CD19 dual-targeting FasTCAR-T GC012F showed 100% minimal residual disease (MRD) negativity and 82.8% MRD negative stringent complete response (sCR) in a predominantly high-risk relapsed/refractory multiple myeloma (RRMM) population Data on GC012F for treatment of B-NHL will be prese...
2023-06-04 02:15
3496
Sanyou launches new European offices and continues to promote global business landscape
SHANGHAI, June 3, 2023 /PRNewswire/ -- In May 2023, following the CIC Boston branch in US, Sanyou opens new offices in The Shard London and CIC Rotterdam respectively, to rapidly promote the globalization of business landscape. Headquartered in Shanghai China, Sanyou Biopharmaceuticals Co., Ltd. ...
2023-06-03 20:05
3500
United Imaging to Unveil Ultra-Modern MRI Technology Platform at ISMRM in Toronto
In addition to the uMR® Jupiter 5T, the 12-year old company will exhibit its uAIFi artificial intelligence technology platform and translational medical research systems, and present an open MR development platform that includes AI-empowered reconstruction. HOUSTON, June 2, 2023 /PRNewswire/ -- ...
2023-06-02 22:00
4451
Trajan's Microsampling Devices Meet IVDR Compliance in Europe, UK
Mitra® and hemaPEN® receive regulatory certification as medical devices for remote blood sample collection in healthcare, clinical trials and home monitoring programs inEurope and United Kingdom. MELBOURNE, Australia, June 2, 2023 /PRNewswire/ -- Trajan Scientific and Medical, a leading provider...
2023-06-02 20:00
2849
TWi Biotechnology Exploring Promising Treatment for Granuloma Annulare (GA)
Company and Yale University Hospital seeking participants with GA for Phase 1 trials of medicine FDA-approved for other ailments NEW HAVEN, Conn., June 2, 2023 /PRNewswire/ -- TWi Biotechnology (TWiB), a clinical stage biopharmaceutical company specializing in development of repositioned drugs f...
2023-06-02 15:51
2012
NMPA accepted Akeso's ebronucimab (PCSK9) marketing application in two cardiovascular indications
HONG KONG, June 1, 2023 /PRNewswire/ -- Akeso Inc. (9926. HK, "Akeso") announced today thatChina's National Medical Products Administration (NMPA) has accepted its New Drug Application (NDA) for its fully human anti-PCSK9 monoclonal antibody ebronucimab (AK102) for 2 indications 1) primary hyper...
2023-06-02 11:43
2159
GC Biopharma receives a business license for the construction of a plasma fractionation plant and technology transfer in Indonesia
* In recognition of securing high-caliber technology in manufacturing plasma derivatives and a track record of overseas plasma fractionation plant construction and technology transfer YONGIN, South Korea, June 1, 2023 /PRNewswire/ -- GC Biopharma, a South Korean biopharmaceutical company, anno...
2023-06-02 08:35
2296
Week's Top Stories
Most Reposted
QDX Co-Founder Giuseppe Barca Awarded Prestigious Gordon Bell Prize, Pioneering Advancements in Drug Discovery Technology
[Picked up by 301 media titles]
2024-11-26 18:49Southeast Asian Consumers Raise Online Security Concerns, New GSMA Survey Shows
[Picked up by 296 media titles]
2024-11-26 13:00TAILG's First Flagship Store in Indonesia Grandly Opens
[Picked up by 283 media titles]
2024-11-22 21:59
MediSun Energy Raises $8.75M Seed Round with Vynn Capital to Drive MENA Expansion and Advance Osmotic Energy Innovation
[Picked up by 280 media titles]
2024-11-25 10:00
ITAP 2024 sets the stage for a more connected advanced factory ecosystem with focus on AI, advanced robotics and sustainability
[Picked up by 271 media titles]
2024-11-28 17:24Most Read
Chinese path to modernization a model for Global South, experts say
2024-11-23 15:35
11178
SUNLU Formnext 2024 Event Highlights: From Functional Filaments to FilaDryer E2
2024-11-23 21:00
7230
Innovative technology and applications recognised with Hong Kong ICT Awards 2024
2024-11-23 02:02
7158
